Abstract:Interest has been recently rekindled in short chain fatty acids (SCFAs) with the emergence of prebiotics and probiotics aimed at improving colonic and systemic health. Dietary carbohydrates, specifically resistant starches and dietary fiber, are substrates for fermentation that produce SCFAs, primarily acetate, propionate, and butyrate, as end products. The rate and amount of SCFA production depends on the species and amounts of microflora present in the colon, the substrate source and gut transit time. SCFAs are readily absorbed. Butyrate is the major energy source for colonocytes. Propionate is largely taken up by the liver. Acetate enters the peripheral circulation to be metabolized by peripheral tissues. Specific SCFA may reduce the risk of developing gastrointestinal disorders, cancer, and cardiovascular disease. Acetate is the principal SCFA in the colon, and after absorption it has been shown to increase cholesterol synthesis. However, propionate, a gluconeogenerator, has been shown to inhibit cholesterol synthesis. Therefore, substrates that can decrease the acetate: propionate ratio may reduce serum lipids and possibly cardiovascular disease risk. Butyrate has been studied for its role in nourishing the colonic mucosa and in the prevention of cancer of the colon, by promoting cell differentiation, cell-cycle arrest and apoptosis of transformed colonocytes; inhibiting the enzyme histone deacetylase and decreasing the transformation of primary to secondary bile acids as a result of colonic acidification. Therefore, a greater increase in SCFA production and potentially a greater delivery of SCFA, specifically butyrate, to the distal colon may result in a protective effect. Butyrate irrigation (enema) has also been suggested in the treatment of colitis. More human studies are now needed, especially, given the diverse nature of carbohydrate substrates and the SCFA patterns resulting from their fermentation. Short-term and long-term human studies are particularly required on SCFAs in relation to markers of cancer risk. These studies will be key to the success of dietary recommendations to maximize colonic disease prevention.

Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications

Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota

Health Benefits and Side Effects of Short-Chain Fatty Acids

Short chain fatty acids in human gut and metabolic health

Short‐chain fatty acids: bridges between diet, gut microbiota, and health

Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health

Gut microbiota derived short-chain fatty acids in physiology and pathology: An update

Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis

Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease

The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease

Role of short-chain fatty acids in host physiology

The Role of Short Chain Fatty Acids in Inflammation and Body Health

Short-Chain Fatty Acids Modulate Healthy Gut Microbiota Composition and Functional Potential

Short-chain fatty acids in diseases

Colonic Health: Fermentation and Short Chain Fatty Acids

SCFA: mechanisms and functional importance in the gut

From gut microbiota dysfunction to obesity: could short-chain fatty acids stop this dangerous course?

Microbiota-derived short chain fatty acids in pediatric health and diseases: from gut development to neuroprotection

Microbial Regulation of Host Physiology by Short-chain Fatty Acids

Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease